Discover Hippo Pathway Regulators with BPS Bioscience’s Exclusive Hippo Pathway TEAD Reporter

BPS Bioscience, Inc. (BPS) is now offering its newest cell line: the Hippo Pathway TEAD Reporter – MCF7 Cell Line.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

San Diego, CA (PRWEB) June 10, 2014

The Hippo pathway is a highly conserved signaling pathway that relays signals from the cell membrane to the nucleus to negatively regulate TEAD-mediated transcription. Increased TEAD transcription can result in increased tumor growth. Alternatively, TEAD transcription leads to regenerative proliferation. Therefore, Hippo pathway activators could serve as cancer therapeutics, while Hippo pathway inhibitors could aid tissue repair in instances such as myocardial infarction. Not surprisingly, researchers are actively striving to identify both activators and inhibitors of TEAD transcription.

BPS’s new Hippo Pathway TEAD Reporter – MCF7 Cell Line is an excellent tool for the investigation of such compounds. The cell line contains the firefly luciferase gene under the control of TEAD responsive elements stably integrated into the MCF7 genome. Hippo pathway responsiveness has been validated in-house using two well-known Hippo pathway activators.

BPS is the first company to offer this cell line, which joins their growing list of cell lines in a portfolio that includes ERK, Notch, Wnt, NF-κB, and Hedgehog signaling reporters. A complete list of cell lines and cell based assay kits available from BPS may be viewed here: http://www.bpsbioscience.com/images/Flyers/Cell_Lines_Assay_Kits.pdf. BPS also offers services for Hippo pathway agonists and antagonists, as well as many other cell signaling pathways; additional details are available at this link:http://bpsbioscience.com/images/Flyers/Cell_Signaling_Services.pdf.

About BPS Bioscience, Inc.

Headquartered in San Diego, California, BPS Bioscience, Inc. is a leading manufacturer of recombinant enzymes and assay kits for life science research. In addition to its extensive portfolio of cell surface receptors, BPS offers reagents for epigenetic, kinase, phosphodiesterase and other areas of active drug discovery. BPS also provides custom protein expression, biochemical and cell based assays, and compound screening and profiling services. BPS has provided products and services to pharmaceutical companies and academic institutes in over 45 countries worldwide, and it continues to expand its portfolio of innovative drug discovery products. By being at the forefront of technology development, BPS focuses on providing quality life science products and services in a timely manner that will help our customers to accelerate drug discovery and development for treatment of human diseases. Visit BPS’s website for more information: http://www.bpsbioscience.com.


Contact